Symbols

SNTI

Senti Biosciences·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

Significant Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SNTI

Senti Biosciences, Inc.

A biotech company that innovating cell and gene therapies using its proprietary gene circuit platform

Industry

Biological Technology

Established Date

03/01/2021

Listing Date

05/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sentibio.com

Security Type

Common stock

Office address

2 Corporate Drive, First Floor, South San Francisco, CA 94080

Business

Introduction

Senti Biosciences, Inc., was incorporated in Delaware on March 1, 2021. The company is a preclinical biotechnology company that develops next-generation cell and gene therapies designed with its gene circuit platform technology to combat challenging diseases. The company's mission is to create a new generation of smarter therapies to defeat complex diseases in a way that traditional medicines cannot. To accomplish this mission, Senti Biosciences has built a synthetic biology platform that it believes may enable it to program the next generation of cells and gene therapies with so-called "gene circuits. ". Created by Senti Biosciences with novel and proprietary combinations of gene parts, these gene circuits are designed to reprogram cells with biological logic to sense inputs, computational decisions, and respond to their respective cellular environments. Senti Biosciences gene circuit platform technology can be applied in a pattern-independent manner for natural killer cells, T cells, tumor-infiltrating lymphocytes, stem cells including hematopoietic stem cells, in vivo gene therapy and messenger ribonucleic acid.

Company Financials

EPS

SNTI has released its 2025 Q3 earnings. EPS was reported at -0.69, versus the expected -0.57, missing expectations. The chart below visualizes how SNTI has performed over recent quarters, highlighting trends in earnings surprises.